Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Genome-wide association studies have begun to elucidate the genetic architecture of type 2 diabetes. We examined whether single nucleotide polymorphisms (SNPs) identified through targeted complementary approaches affect diabetes incidence in the at-risk population of the Diabetes Prevention Program (DPP) and whether they influence a response to preventive interventions. RESEARCH DESIGN AND METHODS: We selected SNPs identified by prior genome-wide association studies for type 2 diabetes and related traits, or capturing common variation in 40 candidate genes previously associated with type 2 diabetes, implicated in monogenic diabetes, encoding type 2 diabetes drug targets or drug-metabolizing/transporting enzymes, or involved in relevant physiological processes. We analyzed 1,590 SNPs for association with incident diabetes and their interaction with response to metformin or lifestyle interventions in 2,994 DPP participants. We controlled for multiple hypothesis testing by assessing false discovery rates. RESULTS: We replicated the association of variants in the metformin transporter gene SLC47A1 with metformin response and detected nominal interactions in the AMP kinase (AMPK) gene STK11, the AMPK subunit genes PRKAA1 and PRKAA2, and a missense SNP in SLC22A1, which encodes another metformin transporter. The most significant association with diabetes incidence occurred in the AMPK subunit gene PRKAG2 (hazard ratio 1.24, 95% CI 1.09–1.40, P = 7 × 10−4). Overall, there were nominal associations with diabetes incidence at 85 SNPs and nominal interactions with the metformin and lifestyle interventions at 91 and 69 mostly nonoverlapping SNPs, respectively. The lowest P values were consistent with experiment-wide 33% false discovery rates. CONCLUSIONS: We have identified potential genetic determinants of metformin response. These results merit confirmation in independent samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Inference of Population Structure Using Multilocus Genotype Data
Pritchard, J. K., Stephens, M., & Donnelly, P. (2000) · Genetics · doi:10.1093/genetics/155.2.945 · Cited by 33,908
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843
Self-citationThe Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · cited 9×
“Category n Candidate genes (n SNPs) 1,256 Comprehensive coverage 1,241 Monogenic diabetes 317 ABCC8 (84), GCK (37), HNF1A (20), HNF1B (74), HNF4A (66), KCNJ11 (9), NEUROD1 (14), PDX1 (13) Monogenic obesity 21 MC4R (21) Previously associated with type 2 diabetes 60 CAPN10 (33), PTPN1 (27) Drug targets 190 PPARG (59), P…”
BackgroundInfluentialWellcome Trust Case Control Consortium, Zeggini, E., Scott, L. J., Saxena, R., Voight, B. F., Marchini, J. L., Hu, T., de Bakker, P. I., Abecasis, G. R., Almgren, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.120 · Cited by 1,864
Self-citationthe GIANT Consortium (2009) · Nature Genetics · doi:10.1038/ng.287 · Cited by 1,720
Efficiency and power in genetic association studies
de Bakker, P. I. W., Yelensky, R., Pe'er, I., Gabriel, S. B., Daly, M. J., & Altshuler, D. (2005) · Nature Genetics · doi:10.1038/ng1669 · Cited by 1,688
Self-citation
Research works printed but not linked: 1
- Li, 2006, Mach 1.0: Rapid haplotype reconstruction and missing genotype inference, Am J Hum Genet S, 79, 2290
Cited by
Items 101–200 of 274
The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs
van Leeuwen, N., Swen, J. J., Guchelaar, H., & Hart, L. M. ‘. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0076-3 · Cited by 32
Chung, J., Cho, S. K., Kim, T. H., Kim, K. H., Jang, G. H., Kim, C. O., Park, E., Cho, J., Jang, I., & Choi, J. H. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283622037 · Cited by 31
Metformin transporter pharmacogenomics: insights into drug disposition—where are we now?
Chan, P., Shao, L., Tomlinson, B., Zhang, Y., & Liu, Z.-M. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541981 · Cited by 32
Anwardeen, N. R., Naja, K., & Elrayess, M. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1506767 · Cited by 33
From Kinases to Diseases: Investigating the Role of AMPK in Human Pathologies
Rey, V., & Tamargo‐Gómez, I. (2023) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases1030012 · Cited by 32
Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus
Le, J., Chen, Y., Yang, W., Chen, L., & Ye, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.004 · Cited by 30
New insights from monogenic diabetes for “common” type 2 diabetes
Tallapragada, D. S. P., Bhaskar, S., & Chandak, G. R. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00251 · Cited by 35
The Complex Interplay of Genetic and Lifestyle Risk Factors in Type 2 Diabetes: An Overview
Franks, P. W. (2012) · Scientifica · doi:10.6064/2012/482186 · Cited by 37
Self-citationClinical perspectives and concerns of metformin as an anti‐aging drug
Wang, C., Chen, B., Feng, Q., Nie, C., & Li, T. (2020) · Aging Medicine · doi:10.1002/agm2.12135 · Cited by 30
Scott, R. A., Chu, A. Y., Grarup, N., Manning, A. K., Hivert, M., Shungin, D., Tönjes, A., Yesupriya, A., Barnes, D. R., Bouatia‐Naji, N., et al. (2012) · Diabetes · doi:10.2337/db11-0973 · Cited by 30
PPARGC1A gene polymorphism is associated with exercise-induced fat loss
Mazur, I. I., Drozdovska, S., Валеріївна, А. О., Vinnichuk, Y., Поліщук, А. О., Dosenko, V., Andreev, I. O., Pickering, C., & Ahmetov, I. I. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05801-z · Cited by 26
Witchel, S. F., Recabarren, S. E., González, F., Diamanti‐Kandarakis, E., Cheang, K. I., Dulęba, A. J., Legro, R. S., Homburg, R., Pasquali, R., Løbo, R. A., et al. (2012) · Endocrine · doi:10.1007/s12020-012-9701-4 · Cited by 30
Xenobiotic Transporters in the Kidney: Function and Role in Toxicity
Shen, H., Scialis, R. J., & Lehman‐McKeeman, L. D. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.12.010 · Cited by 28
Raj, G. M., Mathaiyan, J., Wyawahare, M., & Priyadarshini, R. (2018) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2018-0030 · Cited by 26
Metformin strongly affects transcriptome of peripheral blood cells in healthy individuals
Briviba, M., Silamiķelis, I., Kalniņa, I., Ansone, L., Rovīte, V., Elbere, I., Radoviča-Spalviņa, I., Frīdmanis, D., Aladyeva, E., Konrāde, I., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224835 · Cited by 28
Chen, P., Cao, Y., Chen, S., Liu, Z., Chen, S., & Guo, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10102546 · Cited by 27
Wang, C.-P., Lehman, D. M., Lam, Y.-W. F., Kuhn, J. G., Mahalingam, D., Weitman, S. D., Lorenzo, C., Downs, J. R., Stuart, E. A., Hernández, J., et al. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0425 · Cited by 24
Socratic Seminar with Data: A Strategy to Support Student Discourse and Understanding
Griswold, J. C., Shaw, L., & Munn, M. (2017) · The American Biology Teacher · doi:10.1525/abt.2017.79.6.492 · Cited by 24
Hu, S., Ma, S., Li, X., Tian, Z., Liang, H., Yan, J., Chen, M., & Tan, H. (2019) · BioMed Research International · doi:10.1155/2019/7398063 · Cited by 24
Leveraging Genetics to Advance Type 2 Diabetes Prevention
Florez, J. C. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002102 · Cited by 25
Self-citationHuman intelectin‐2 (ITLN2) is selectively expressed by secretory Paneth cells
Nonnecke, E. B., Castillo, P. A., Johansson, M., Hollox, E. J., Shen, B., Lönnerdal, B. L., & Bevins, C. L. (2022) · The FASEB Journal · doi:10.1096/fj.202101870r · Cited by 23
Pharmacogenetics of Antidiabetic Drugs
Srinivasan, S., Yee, S. W., & Giacomini, K. M. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.04.005 · Cited by 27
Tkáč, I., Javorský, M., Klimčáková, L., Židzik, J., Gaľa, I., Babjaková, E., Schroner, Z., Štolfová, M., Hermanová, H., & Habalová, V. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1774-y · Cited by 25
Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs
Daniels, M. A., Kan, C., Willmes, D. M., Ismail, K., Pistrosch, F., Hopkins, D., Mingrone, G., Bornstein, S. R., & Birkenfeld, A. L. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.54 · Cited by 24
Niu, N., Liu, T., Cairns, J., Ly, R. C., Tan, X., Deng, M., Fridley, B. L., Kalari, K. R., Abo, R., Jenkins, G. D., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw301 · Cited by 24
Billings, L. K., Jablonski, K. A., Warner, A. S., Cheng, Y.-C., McAteer, J. B., Tipton, L., Shuldiner, A. R., Ehrmann, D. A., Manning, A. K., Dabelea, D., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3429 · Cited by 20
Self-citationAssociation of AMP-Activated Protein Kinase with Risk and Progression of Non–Hodgkin Lymphoma
Hoffman, A. E., Demanelis, K., Fu, A., Zheng, T., & Zhu, Y. L. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1014 · Cited by 20
Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy
Staiger, H., Schaeffeler, E., Schwab, M. G., & Häring, H. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.363 · Cited by 21
Nasykhova, Y. A., Barbitoff, Y. A., Tonyan, Z. N., Danilova, M. M., Nevzorov, I. A., Komandresova, T. M., Mikhailova, A. A., Vasilieva, T., Glavnova, O. B., Yarmolinskaya, M. I., et al. (2022) · Genes · doi:10.3390/genes13081310 · Cited by 21
Calza, G., Nyberg, E., Mäkinen, M., Soliymani, R., Cascone, A., Lindholm, D., Barborini, E., Baumann, M., Lalowski, M. M., & Eriksson, O. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00141 · Cited by 19
Ebid, A. I. M., Ehab, M., Ismail, A., Soror, S. H. A., & Mahmoud, M. A. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1619571 · Cited by 21
Jones, V., Dietze, E. C., Jovanović‐Talisman, T., McCune, J. S., & Seewaldt, V. L. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.509714 · Cited by 19
Molecular action and pharmacogenetics of metformin: current understanding of an old drug
Rena, G., Pearson, E. R., & Sakamoto, K. (2012) · Diabetes Management · doi:10.2217/dmt.12.42 · Cited by 22
Metformin Pharmacogenomics: Biomarkers to Mechanisms
Wang, L., & Weinshilboum, R. M. (2014) · Diabetes · doi:10.2337/db14-0609 · Cited by 19
Khatami, F., Mohajeri‐Tehrani, M. R., & Tavangar, S. M. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190228102212 · Cited by 21
Genotype-Based Recall Studies in Complex Cardiometabolic Traits
Franks, P. W., & Timpson, N. J. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.001947 · Cited by 18
Self-citationOut, M., Becker, M. L., van Schaik, R. H., Lehert, P., Stehouwer, C. D. A., & Kooy, A. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0010 · Cited by 20
Pharmacogenetics of Oral Antidiabetic Therapy
Ordelheide, A., de Angelis, M. H., Häring, H., & Staiger, H. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0195 · Cited by 18
Gene-Physical Activity Interactions and Their Impact on Diabetes
Kilpeläinen, T. O., & Franks, P. W. (2014) · Medicine and sport science/Medicine and sport · doi:10.1159/000357339 · Cited by 18
Self-citationRandrianarisoa, E., Lehn‐Stefan, A., Krier, J., Böhm, A., Heni, M., de Angelis, M. H., Fritsche, A., Häring, H., Stefan, N., & Staiger, H. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz020 · Cited by 17
Xu, X., Qian, D., Liu, H., Cruz, D., Luo, S., Walsh, K. M., Abbruzzese, J. L., Zhang, X., & Wei, Q. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23018 · Cited by 16
Does Metformin Work for Everyone? A Genome-wide Association Study for Metformin Response
Florez, J. C. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0220-0 · Cited by 16
Self-citationSchweighofer, N., Lerchbaum, E., Trummer, O., Theiler‐Schwetz, V., Pieber, T. R., & Obermayer-Pietsch, B. M. (2014) · Pharmacogenomics · doi:10.2217/pgs.13.223 · Cited by 17
Clinical and genetic predictors of diabetes drug’s response
Fodor, A., Cozma, A., Suharoschi, R., Sitar-Tăut, A., & Román, G. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1656226 · Cited by 16
Chang, H. H., Hsueh, Y., Cheng, Y. W., Ou, H., & Wu, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071720 · Cited by 18
Vohra, M., Sharma, A., Mallya, S. D., Prabhu, N. B., Jayaram, P., Nagri, S. K., Umakanth, S., & Rai, P. S. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01989-y · Cited by 15
Exercise training, genetics and type 2 diabetes‐related phenotypes
Hagberg, J. M., Jenkins, N. T., & Spangenburg, E. E. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2012.02455.x · Cited by 19
Statistical power considerations in genotype-based recall randomized controlled trials
Atabaki‐Pasdar, N., Ohlsson, M., Shungin, D., Kurbasic, A., Ingelsson, E., Pearson, E. R., Ali, A., & Franks, P. W. (2016) · Scientific Reports · doi:10.1038/srep37307 · Cited by 15
Self-citationWalker, C. G., Loos, R. J. F., Mander, A., Jebb, S. A., Frost, G. S., Griffin, B. A., Lovegrove, J. A., Sanders, T. A. B., & Bluck, L. J. C. (2012) · Genes & Nutrition · doi:10.1007/s12263-012-0284-8 · Cited by 13
Updates of precision medicine in type 2 diabetes
Xia, M., & Li, X. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12 · Cited by 13
Association of NAT2 Polymorphisms with Type 2 Diabetes in a Population from Bosnia and Herzegovina
Semiz, S., Dujić, T., Ostanek, B., Velija-Ašimi, Z., Prnjavorac, B., Bego, T., Malenica, M., Mlinar, B., Heljić, B., Marc, J., et al. (2011) · Archives of Medical Research · doi:10.1016/j.arcmed.2011.06.007 · Cited by 13
Damarov, I. S., Korbolina, E. E., RYKOVA, E. Y., & Merkulova, T. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179297 · Cited by 15
Masilela, C. M., Pearce, B., Ongole, J. J., Adeniyi, O. V., & Benjeddou, M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020104 · Cited by 12
Tzvetkov, M. V., Dalila, N., & Faltraco, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-23793-0_4 · Cited by 12
Liang, H., Xu, W., Zhou, L., Yang, W., & Weng, J. (2017) · Diabetic Medicine · doi:10.1111/dme.13351 · Cited by 12
Billings, L. K., Jablonski, K. A., Pan, Q., Florez, J. C., Franks, P. W., Goldberg, R. B., Hivert, M.-F., Kahn, S. E., Knowler, W. C., Lee, C. G., et al. (2024) · Diabetes · doi:10.2337/db23-0761 · Cited by 11
Self-citationMicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program
Flowers, E., Aouizerat, B. E., Kanaya, A. M., Florez, J. C., Gong, X., & Zhang, L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac714 · Cited by 11
Self-citationPalomaki, G. E., Melillo, S. N., Marrone, M. T., & Douglas, M. P. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.8 · Cited by 11
Song, H., Makino, Y., Noguchi, E., & Arinami, T. (2014) · Clinical Case Reports · doi:10.1002/ccr3.167 · Cited by 12
Using Personalized Medicine in the Management of Diabetes Mellitus
Elk, N., & Iwuchukwu, O. F. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1976 · Cited by 12
Mostafa‐Hedeab, G., Mohamed, A. A., Thabet, G., Sabry, D., Salam, R., & Hassan, M. E. (2018) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1356 · Cited by 13
Xiao, D., Liu, J., Zhang, S., Liu, R., Yin, J., Han, X., Li, X., Zhang, W., Chen, X., Zhou, H., et al. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s305020 · Cited by 11
Predictors of HbA1c levels in patients initiating metformin
Martono, D. P., Hak, E., Heerspink, H. J. L., Wilffert, B., & Denig, P. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1227774 · Cited by 13
Díaz, M., López‐Bermejo, A., Sánchez‐Infantes, D., Bassols, J., de Zegher, F., & Ibáñez, L. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.04.075 · Cited by 11
Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
Taber, K. J., & Dickinson, B. D. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s75583 · Cited by 16
Zolotov, S., Yosef, D. B., Rishe, N. D., Yesha, Y., & Karnieli, E. (2011) · Personalized Medicine · doi:10.2217/pme.11.36 · Cited by 12
Chen, P., Cao, Y., Guo, Y., Xu, Q., Wang, X., Zhang, L., Liu, Z., Chen, D., Chen, S., & Chen, S. (2021) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000454 · Cited by 9
Bassols, J., Megía, A., Soriano‐Rodríguez, P., Díaz, M., Prats‐Puig, A., Gifre, M., Simón‐Muela, I., Torrent, S., Borrell, A. C., Riera-Socasau, J.-C., et al. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.04.037 · Cited by 10
Pau, C. T., Cheang, K. I., Modi, B. P., Kasippillai, T., Keefe, C. C., Shulleeta, M., Evans, W. S., Pal, L., Strauss, J. F., Nestler, J. E., et al. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0079 · Cited by 10
Genetics of Drug Response in Type 2 Diabetes
Tkáč, I. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0617-2 · Cited by 10
Pro-aging effects of chronic glucocorticoid signaling
Lambertucci, F., Castinetti, F., Martins, I., López-Otín, C., & Kroemer, G. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.05.002 · Cited by 8
Identification and functional characterization of novel MATE1 genetic variations in Koreans
Kim, T. H., Kim, K. H., Park, H., Kim, S., & Choi, J. H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.072 · Cited by 8
STOCKER, S. L., Riedmaier, A. E., Schwab, M. G., & Giacomini, K. M. (2013) · Wiley eBooks · doi:10.1002/9781118353240.ch8 · Cited by 9
Xiao, D., Zhang, S., Li, X., Yin, J., Gong, W., Zheng, Y., Xu, X., Lin, X., Ji, L., Liu, R., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.95 · Cited by 8
Anguita‐Ruiz, A., Pastor‐Villaescusa, B., Leis, R., Bueno, G., Hoyos, R., Vázquez‐Cobela, R., Latorre-Millán, M., Cañete, M. D., Caballero‐Villarraso, J., Gil, Á., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091471 · Cited by 10
Pharmacoepigenetics in type 2 diabetes: is it clinically relevant?
Ling, C. (2022) · Diabetologia · doi:10.1007/s00125-022-05681-x · Cited by 8
Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes
Engelbrechtsen, L., Galijatovic, E. A. A., Roepstorff, S., Hansen, T. F., & Vestergaard, H. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000160 · Cited by 8
Challenges of Implementing Personalized (Precision) Medicine: A Focus on Diabetes
Fodor, A., & Karnieli, E. (2016) · Personalized Medicine · doi:10.2217/pme-2016-0022 · Cited by 8
Pharmacogenetics in type 2 diabetes: still a conundrum in clinical practice
Brunetti, A., CHIEFARI, E. D., & FOTI, D. P. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1316192 · Cited by 8
Imangaliyeva, A., Sikhayeva, N. S., Baidurin, S. A., Suleimenova, B. A., Romanova, A. A., Zholdybayeva, E. V., Shaimerdenov, S. A., Kuanysheva, A. S., & Bolatov, A. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/1568889 · Cited by 7
Identification of Novel Intronic SNPs in Transporter Genes Associated with Metformin Side Effects
Schweighofer, N., Strasser, M., Obermayer, A. M., Trummer, O., Sourij, H., Sourij, C., & Obermayer-Pietsch, B. M. (2023) · Genes · doi:10.3390/genes14081609 · Cited by 7
Morales-Rivera, M. I., Alemón‐Medina, R., Martínez-Hernández, A. G., Contreras-Cubas, C., Altamirano-Bustamante, N. F., Gómez-Garduño, J., Mendoza‐Caamal, E., Nunez-Gonzalez, J., García‐Álvarez, R., Revilla, M., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101385 · Cited by 9
Kalamajski, S., Huang, M. N., Dalla‐Riva, J., Keller, M., Dawed, A. Y., Hansson, O., Pearson, E. R., Mulder, H., & Franks, P. W. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab266 · Cited by 7
Self-citationAladhab, R. A., Abd, A. H., Alidrisi, H. A., & Alabbood, M. (2023) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2699 · Cited by 8
Metformin and other biguanides: pharmacology and therapeutic usage
Samson, S. L., & Garber, A. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch43 · Cited by 9
Webb, A., Papp, A. C., Sanford, J. C., Huang, K., Parvin, J. D., & Sadée, W. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835ff536 · Cited by 6
Lam, Y. W. F. (2014) · Apple Academic Press eBooks · doi:10.1201/b17137-6 · Cited by 6
Kim, H., Bae, S., Yoon, H. Y., Yee, J., & Gwak, H. S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac333 · Cited by 7
Gene-Diet Interactions in Type 2 Diabetes
Cornelis, M. C. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0095-1 · Cited by 8
Yee, S. W., Zhou, K., & Giacomini, K. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_22 · Cited by 6
Pharmacogenetic Factors That Affect Drug Metabolism and Efficacy in Type 2 Diabetes Mellitus
Li, X., & Liu, Z. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802949-7.00007-9 · Cited by 10
Brunetti, A. (2014) · World Journal of Translational Medicine · doi:10.5528/wjtm.v3.i3.141 · Cited by 7
Ando, H., Nakano, K., Ushijima, K., Kurokawa, S., Washino, S., Hosohata, K., Morita, T., & Fujimura, A. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.03.002 · Cited by 5
Virginia, D. M., Wahyuningsih, M. S. H., & Nugrahaningsih, D. A. A. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.6213 · Cited by 5
Wu, H., Liu, N., YANG, Z. K., Tao, X., Du, Y., Wang, X., Lü, B., Zhang, Z., Hu, R., & Wen, J. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-107 · Cited by 5
Genetics and response to treatment with metformin for type 2 diabetes
Tessier, L., St-Amour, S., Simard, D., Bouchard, J., Perron, P., & Tremblay, K. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2565992 · Cited by 5
Jouabadi, S. M., Peymani, P., Shahraki, M. N., van Rooij, J., Broer, L., Roks, A. J. M., Stricker, B. H. C., & Ahmadizar, F. (2024) · The Pharmacogenomics Journal · doi:10.1038/s41397-024-00352-z · Cited by 6
Type 2 diabetes mellitus: Clinical aspects of genetics, nutrigenetics, and pharmacogenetics
As, A., Kamynina, L. L., & Akhmedova, Z. G. A. (2015) · Terapevticheskii arkhiv · doi:10.17116/terarkh2015878124-131 · Cited by 4
The Role of Pharmacogenomics in Diabetes
Lam, Y. W. F., Duggirala, R., Jenkinson, C. P., & Arya, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00009-7 · Cited by 4
Yu, H., Hu, W., Lin, C., Xu, L., Liu, H., Luo, L., Chen, R., Huang, J., Chen, W., Yang, C., et al. (2021) · Adipocyte · doi:10.1080/21623945.2021.1978728 · Cited by 4
Metadata
- Authors
- Jablonski, K. A., McAteer, J. B., de Bakker, P. I. W., Franks, P. W., Pollin, T. I., Hanson, R. L., Saxena, R., Fowler, S., Shuldiner, A. R., Knowler, W. C., Altshuler, D., Florez, J. C., & for the Diabetes Prevention Program Research Group
- Affiliations
- George Washington University (US)
- Broad Institute (US)
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts;
- Lund University (SE)
- University of Maryland, Baltimore (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts;
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-08-03
- Volume
- 59
- Issue
- 10
- Pages
- 2672-2681
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3279522
- OpenAlex
- W2137393786
- Cited by
- 271
- References
- 35
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 10 · 2023: 17 · 2022: 12 · 2021: 13 · 2020: 16 · 2019: 18 · 2018: 19 · 2017: 21 · 2016: 24 · 2015: 18 · 2014: 25 · 2013: 25 · 2012: 23
- FWCI
- 11.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072041, U01DK048489)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, single nucleotide polymorphisms, metformin response, lifestyle intervention, Diabetes Prevention Program, SLC47A1, AMPK, PRKAG2, STK11, PRKAA1, PRKAA2, SLC22A1, genetic susceptibility, gene-environment interaction, diabetes prevention
- MeSH terms
- Adult, Diabetes Mellitus, Diabetes Mellitus, Type 2, Ethnicity, Female, Genotype, Hemeproteins, Humans, Life Style, Male, Metformin, Middle Aged, Genetic Variation, Body Mass Index, Incidence, Polymorphism, Single Nucleotide, Organic Cation Transport Proteins, Racial Groups, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.